Profile of Patients Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections in Bhutan
Open Access
- 1 June 2023
- journal article
- research article
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 17, 1565-1573
Abstract
Purpose: Ocular vascular diseases are common causes of visual impairment and blindness, for which anti-vascular endothelial growth factor (anti-VEGF) is the first-line therapy. Current study describes the profile of patients receiving intravitreal anti-VEGF injections (IVI), and gender variation in Bhutan. The study was designed to inform national health policy. Study Design: Retrospective cross-sectional study. Methods: We reviewed the surgical registers of the vitreoretinal (VR) units across Bhutan over three years. Patient demography, clinical findings, diagnostic tests performed, and diagnoses or indications for IVI were logged. A descriptive analysis was performed. Results: Despite limited availability of anti-VEGF, a total of 381 patients received IVI in operating theatres as mandated by the national guidelines. The majority of patients were males (230, 60.4%, p = 0.004). The mean age was 65.2 ± 13.5 years (range 13 years to 90 years), and a median of 69 years. The majority of the treated eyes (117, 30.7%) had BCVA < 3/60 to light perception (PL), and another 51 eyes (13.4%) had < 6/60 to 3/60. The most common indication for IVI was neovascular age-related macular degeneration (nAMD) (168 cases, 42.2%), followed by retinal vein occlusion (RVO) (132 cases, 34.6%), diabetic macular oedema (DMO) and retinopathy (DR) (50 cases, 13.1%), and myopic choroidal neovascular membrane (11 cases, 0.03%). Conclusion: Limited human resources for managing VR diseases in Bhutan are compounded by economic and geographic challenges. With increasing VR diseases such as nAMD and myopia and complications of systemic diseases such as DR, DMO and RVO, there is a need to improve VR services. Currently, anti-VEGF is procured only for a pooled patients requiring IVI, and patients are lost due to longer waiting periods. Bhutan needs to assess if females are reporting less or are not receiving treatment due to cultural barriers and social stigma.Keywords
This publication has 49 references indexed in Scilit:
- Diabetes and hypertension in urban bhutanese men and womenIndian Journal of Community Medicine, 2013
- Medication Adherence in the General PopulationPLOS ONE, 2012
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Global Prevalence and Major Risk Factors of Diabetic RetinopathyDiabetes Care, 2012
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- Retinal Vein Occlusions2010
- Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: Same or different disease?Progress in Retinal and Eye Research, 2010
- Pegaptanib Sodium for Macular Edema Secondary to Central Retinal Vein OcclusionArchives of Ophthalmology (1950), 2009
- INDOCYANINE GREEN VIDEOANGIOGRAPHY OF IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHYRetina, 1995
- Natural History of Choroidal Neovascularization in Degenerative MyopiaOphthalmology, 1984